News and Trends 21 Jun 2016
Allergy Immunotherapy Knocked Out in Phase III by an ‘Overperforming Placebo’
Circassia’s pipeline takes a major step back as its therapy for cat allergy gets disappointing results — it had the same effect as the placebo. Stocks promptly sank by 65%. The Oxford-based Circassia has been a major European player in the field of allergy immunotherapies. It made a splash when it raised €267.7M in the London Stock […]